The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Patients with RA Who Respond to Treatment Experience Increased Cholesterol

Patients with RA Who Respond to Treatment Experience Increased Cholesterol

June 6, 2016 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Heart_BrandX_GettyImages_500x270Patients with rheumatoid arthritis (RA) experience an increased risk of cardiovascular disease. What is unclear, however, is the role that disease-modifying anti-rheumatic drug (DMARD) therapy plays in that risk. In an effort to investigate the question, Christina Charles-Schoeman, MD, MS, a rheumatologist at Ronald Reagan UCLA Medical Center in Los Angeles, and colleagues analyzed data from the Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) trial and published their results in the March issue of Arthritis & Rheumatology.1 In their paper, the researchers described the cholesterol data from the first randomized, placebo-controlled, long-term study of early RA patients.

You Might Also Like
  • Cholesterol Levels in Patients with RA Starting Methotrexate
  • Statin Guideline Eliminates Cholesterol Treat-to-Target Strategy for Managing Atherosclerotic Cardiovascular Risk
  • Study Points to Need for Increased Antirheumatic Therapy in Patients with Dyslipidemia
Also By This Author
  • GI Disease in Early Systemic Sclerosis Associated with Worse Outcomes

TEAR included a population of patients with very early RA. These individuals were primarily seropositive and had high disease activity at baseline. As expected, both body mass index (BMI) and smoking use were strongly associated over time with higher total cholesterol, low-density lipoprotein cholesterol (LDL-C) and total cholesterol/high-density lipoprotein cholesterol (HDL-C) ratios, as well as lower HDL-C levels. Of the 416 patients participating in the two-year trial, three died from cardiac disorders.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The investigators analyzed the relationship between treatment and cholesterol levels and found that patients treated with either biologic or non-biologic therapies who experienced decreases in RA disease activity also had increases in cholesterol. “It really confirms what we have thought,” explains Dr. Charles-Schoeman in an interview with The Rheumatologist. Specifically, decreased inflammation was associated with increased cholesterol levels (total cholesterol, LDL-C and HDL-C).

Dr. Charles-Schoemen explains that rheumatologists have noticed this effect in the clinic and some, along with their patients, have become concerned. However, she points out that, “In terms of what it means, we don’t know yet.” As she notes, although lipoprotein is frequently analyzed for its role in carrying cholesterol and influencing risk for cardiovascular disease, lipoprotein plays other roles as well, one or more of which may be affected by RA treatments. In particular, Dr. Charles-Schoeman describes HDL as a very interesting and complicated particle that likely has multiple biological functions.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In all treatment groups, changes in cholesterol levels were associated with decreases in inflammation as measured by C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and disease activity score (DAS28). Thus, the therapies effectively treated RA, while simultaneously increasing cholesterol levels. When the investigators looked more closely at the cohort, they found that two years of triple therapy was associated with a higher HDL-C, and lower LDL-C and total cholesterol/HDL-C ratios when compared with two years of methotrexate (MTX) monotherapy or MTX + etanercept (ETA). Although the patients who responded to therapy had marked increases in cholesterol at six months, these changes were not maintained throughout the two-year trial.

Pages: 1 2 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: cardiovascular, Cardiovascular disease, cholesterol, Rheumatoid Arthritis (RA), risk, triple therapy

You Might Also Like:
  • Cholesterol Levels in Patients with RA Starting Methotrexate
  • Statin Guideline Eliminates Cholesterol Treat-to-Target Strategy for Managing Atherosclerotic Cardiovascular Risk
  • Study Points to Need for Increased Antirheumatic Therapy in Patients with Dyslipidemia
  • Cardiovascular Disease Risk High in RA Patients

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)